(News Bulletin 247) – Degroof Petercam renewed its buy recommendation on Carmat on Thursday, with a price target of 20.2 euros, following annual results deemed ‘unsurprising’.
After a 2022 financial year marked by the resolution of quality problems on its artificial heart, the year 2023 will be that of the recovery of activity, estimates the Belgian investment house in a research note.
According to Degroof, the two main challenges facing the company today are (1) the take-off of production necessary to achieve its annual objectives and (2) the extension of its financial visibility beyond July 2023. .
In the short term, it is nevertheless the approval of the FDA for the resumption of the feasibility study in the United States which should constitute the main catalyst for the value, continues the Brussels firm.
Degroof Petercam points out that Carmat has planned to keep the market regularly informed of the progress of its Aeson core, which should allow investors to better understand the dynamics from which the company will benefit this year.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
